论文部分内容阅读
Protalix生物治疗药公司宣布,在小鼠法布雷病模型上pegunigalsidase alfa,与市售酶替代治疗药及未给予治疗的小鼠比较,证实可延缓小纤维神经病发展。此次临床前研究中,该药1 mg/kg、市售药β阿加糖苷酶(Fabrazyme)和α阿加糖苷酶(Replagal)分别为1和0.2 mg/kg,给法布雷病小鼠每2周1次静脉滴注,与不给药法布雷病小鼠和野生型健康小鼠进行比较,共3个月。用α半乳糖苷酶治疗的法布雷病小鼠,与不给药法
Protalix Biotherapeutics announced that pegunigalsidase alfa, a mouse model of Fabry disease, has been shown to delay the development of small fiber neuropathy when compared with commercially available enzyme-replacement therapies and untreated mice. In this preclinical study, the drug 1 mg / kg, the commercially available drugs Fabrazyme and αplasgoside were 1 and 0.2 mg / kg, respectively, to mice with Fabre disease 2 weeks, 1 intravenous infusion, with no administration of Fabre disease and wild-type healthy mice were compared for 3 months. Fabre mice treated with alpha-galactosidase, with no administration